$XBI $124.82 +0.7%
Covid Updates
$SRNE -1.8% Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS-C. source
$VNDA +0.1% Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And
Placebo In Hospitalized COVID-19 Pneumonia Patients. source
Pipeline Updates
$KNSA -15.7% Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity. source
$LVTX +18.5% on 7/27 LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary. source
$MRNA +11.5% Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345). source
$MRNS -8.2% Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone. source
$MRNS -8.2% Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update. source
$ARCT +68.1% Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study. source
$RYTM -4.5% Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity. source
$SWTX +0.4% SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations. source
$OTLK +6.6% Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD. source
$ABCL -0.4% Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer. source
$ANGN +4.5% Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021. source
Financial Updates
$CRMD -1.8% INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of CorMedix Inc. (CRMD) Investors. source
$SRRK -11.9% Scholar Rock Announces Leadership Change. source
$TBIO +37.7% Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development. source
Posted by FS
Comments